Beta Drugs Limited (NSE:BETA)

Market Cap	19.23B
Revenue (ttm)	3.62B
Net Income (ttm)	424.19M
Shares Out	10.09M
EPS (ttm)	42.02
PE Ratio	45.34
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,620
Average Volume	5,366
Open	1,880.05
Previous Close	1,900.00
Day's Range	1,880.05 - 1,934.95
52-Week Range	1,429.52 - 2,215.24
Beta	-0.33
RSI	58.86
Earnings Date	Aug 6, 2025

About Beta Drugs

Beta Drugs Limited develops, manufactures, and sells anti-cancer drugs in India. The company offers oncology products in the areas of breast, lung, head and neck, colorectal, ovarian, gastric, testicular, renal, and prostate cancer, as well as brain tumor, leukemia, lymphoma, myeloma, and supportive cancer; and dermatology products. It also develops active pharmaceutical ingredients. The company exports its products. Beta Drugs Limited was incorporated in 2005 and is based in Panchkula, India.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2005
• Employees: 371
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: BETA

Financial Performance

In 2024, Beta Drugs's revenue was 3.62 billion, an increase of 22.54% compared to the previous year's 2.96 billion. Earnings were 424.19 million, an increase of 16.42%.